Deep Track Capital Discloses New 5.81% Stake in Avalo Therapeutics, Inc. (AVTX)

On May 29, 2026, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, filed a Schedule 13G with the SEC disclosing a new ownership stake in Avalo Therapeutics, Inc. (AVTX). The reporting persons collectively hold 3,055,027 shares of common stock, representing 5.81% of the company's outstanding shares based on the issuer's 10-Q filed on May 13, 2026. This filing follows an event date of May 22, 2026. The reporting group shares voting and dispositive power over the entire holding. David Kroin, as the Managing Member of the General Partner of the Investment Adviser and Director of the Master Fund, may be considered a control person for the entities involved. The filing indicates that the acquisition was made in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This initial disclosure marks a significant increase from zero reported holdings in the previous period.